• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to hydrogel microbeads comprising at least water, chitosan, at least one polyphosphate compound, the water being present at a concentration of at least 85% by weight, of hydrogel, said microbeads having a number average diameter ranging from 100 to 900 μm. The present invention also relates to their manufacturing process and their uses, in particular in pharmaceutical compositions or medical devices, more particularly for the treatment of a pathology of a joint.
    公开号:FR3029790A1
    申请号:FR1462367
    申请日:2014-12-12
    公开日:2016-06-17
    发明作者:Renaud Lecler；Mickael Chausson；Pierre Douette；Guillem Rocasalbas；Sandrine Gautier
    申请人:SYNOLYNE PHARMA；
    IPC主号:
    专利说明:

    [0001] The present invention relates to hydrogel microbeads, their method of manufacture and their uses, in particular in pharmaceutical compositions or medical devices, more particularly for the treatment of a pathology of a joint. Chitosan is a naturally occurring polymer of known interest for many years. This polysaccharide can be obtained from animal sources such as from crustacean shell, but also from fungal sources from fungal cell walls. Chitosan is for example used in the form of matrix to encapsulate active ingredients. It is usually used as a pharmaceutical vehicle. These vehicles may be in solid form, particularly when they are dried or lyophilized. Many patents relate to this technology.
    [0002] In parallel with this technology, particles based on chitosan in the form of hydrogel, of different dimensions, have developed. These compositions have a particularly high level of water making them very different from the aforementioned matrices. In general, water represents more than 85% or even more than 90% by weight of the composition. Such hydrogel particles have a composition and properties very different from the chitosan matrices mentioned above. Such hydrogel particles are especially used in tissue engineering or also as vectors of active compounds. However, any hydrogel is not suitable for forming beads that can be easily injected into the human or animal body.
    [0003] It is known from EP 2538987 B1 (US 20120321678) hydrogel beads based on chitosan and alginate, in particular for their use in intra-articular supplementation. It is in this patent to improve the effects of a hydrogel by combining it with hydrogel beads, usable at least in this specific application. In particular, these beads have a life time after injection at the intra-articular high level as well as interesting mechanical properties where the injection is performed. Such beads are particularly interesting because of their properties, in particular their elastic properties, provided during the intra-articular injection. The hydrogel beads according to this patent, however, have trabeculae. Trabeculae are fibrillar or filamentous species present inside the hydrogel.
    [0004] The application WO 2009/150651 still describes a hydrogel based on the combination of two solutions of chitosan of different characteristics, starting from an acid solution brought gradually to neutral pH. The first chitosan is highly acetylated with a degree of acetylation of between 40% and 60%. The second chitosan is highly deacetylated with a degree of acetylation of at most 20%. Such hydrogels are sensitive to temperature which allows them to gel in situ, after injection into the human or animal body. The application does not teach how to form hydrogel particles. The present invention aims to provide chitosan hydrogel particles. It is another object of the present invention to provide chitosan hydrogel particles which are higher in concentration than some prior hydrogel beads, having about 0.5% by weight of chitosan based on the mass of the while retaining good mechanical properties, particularly for intra-articular injection applications. The present invention further aims to improve the stability of chitosan beads. In particular, the present application aims to provide hydrogel beads that do not have solid particles, such as trabeculae.
    [0005] It is another object of the present invention to provide hydrogel beads having a composition comprising chitosan, optionally in admixture with other compounds. This composition is advantageously homogeneous. It appears from the state of the art that the preparation of such hydrogel beads is not easy since EP 2538987 B1 describes the formation of trabeculae and the application WO 2007/13514 recommends the use of a derivative. of chitosan to overcome the technical problem of solid particle formation. The present invention also aims to provide hydrogel beads whose manufacturing process is industrializable, preferably by limiting the manufacturing costs and ensuring good reproducibility of the particles thus manufactured.
    [0006] In particular, the object of the present invention is to simplify the manufacturing process, in particular by reducing the variability of the process, a variability which is found in particular when several biopolymers are used as chitosans of different nature or mixtures of chitosan and alginate, and in particular by reducing the number of process steps and the number of raw materials to be used.
    [0007] In particular, the present invention aims to avoid the preparation of a preliminary solution containing alginate, while retaining the hydrogel character of the microbeads, ie the ability to remain stable while retaining a large amount of water, and to remain deformable and elastic compression.
    [0008] Advantageously, the object of the invention is to provide microbeads having good properties, for example good mechanical properties for the intended applications, and more specifically for intra-articular injections, for example good elastic properties and absorption properties. shocks, good crush resistance, and good adhesion to tissue.
    [0009] In this regard, the hydrogel beads according to the prior art method described in EP 2538987 B1 have a large diameter. The article by Oprenyeszk et al. 2013, shows that such particles have a diameter of 600 to 900 micrometers (lm). The hydrogel beads are therefore not suitable for intra-articular injections which require thin needles of small diameter, especially in the context of articular diseases treated by intra-articular viscosupplementation and chronic joint diseases. Such diseases are typically cartilage pathologies, which cause cartilage damage and defects and joint pain, such as osteoarthritis, for example due to aging or an accident. To ensure ease of injection by the practitioner, increase the comfort of the patient, limit the risk of misplaced injection and avoid the risk of infection, especially during repeated injections, it is appropriate to use fine needles . The present invention therefore still aims to provide an injectable composition intra-articularly which facilitates repeated injections, in particular through fine needles such as for example 18 to 22 Gauge type needles as recommended for most viscosupplementation products currently marketed, especially above 21 Gauge, or possibly even finer, for example 23 Gauge. It is therefore desired to develop microbeads whose properties and diameter distribution can be adjusted so that they can be easily injected through fine needles, in particular microbeads with a number average diameter of less than 900 μm, preferably less than 800 μm, preferably less than 700 μm, and more preferably whose D (0.9) is less than 900 μm, preferably less than 800 μm, preferably less than 700 μm. It has been discovered that the technical problems mentioned above can be solved by the present invention. In particular, the invention employs a specific method of making chitosan-based hydrogel microbeads, which does not include forming solid trabeculae in the microbeads, thereby avoiding the disadvantages mentioned in the prior art. , in a surprising way. It is apparent from reading the prior art discussed above that the solution provided by the present invention was not obvious to those skilled in the art. Moreover, the microbeads of the invention make it possible to increase the proportion of chitosan. For this purpose, the principle of gelling alginate by a calcium ion is not the principle that is implemented. Indeed, the invention uses the principle of the crosslinking of chitosan by polyphosphate ions to obtain a composition of chitosan hydrogel. It is already known to form solutions of chitosan in the presence of sodium beta-glycerophosphate, for example solutions of chitosan and beta-glycerophosphate having the property of gelling when the temperature increases, for example at the temperature of the human body. It is also known to stabilize solid and dry microspheres of chitosan by combining it with sodium tripolyphosphate. It is still known to form complexes based on chitosan and phytic acid (inositol hexakisphosphate) in solution, or even millimetric size capsules composed of chitosan and phytic acid. However, the prior art does not assume the possibility of forming microbeads of chitosan which are in the form of a hydrogel and having properties suitable for their passage through a needle of diameter adapted to perform intra-articular injections, for example. for example, to treat a pathology of a joint, such as for example a cartilage lesion, particularly in a human being. The present invention also makes it possible to increase the stability of chitosan by acting on the non-covalent crosslinking of chitosan, and not on the gelling of alginate in the presence of a calcium ion, via the chelation of the calcium ion by alginate. In particular, it was not obvious to the person skilled in the art that the combination of chitosan with a polyphosphate compound would have made it possible to obtain hydrogel beads with good properties, in particular mechanical properties, for intra-articular injection, for example. viscosupplementation, and injectable through a thin needle. The invention more specifically relates to a hydrogel particle or ball, and more particularly to a hydrogel microbead.
    [0010] Thus, the present invention relates to a hydrogel microbead comprising at least water, chitosan, at least one polyphosphate compound, the water being present at a concentration of at least 85% by weight of hydrogel, said Ball having a number average diameter ranging from 100 to 900 lm In particular, "ball" is understood to mean a particle of substantially spherical shape. Such a shape can be appreciated by microscope. Such a ball may have inherent imperfections in the manufacturing process. The term "microbead" means a ball having a size less than 1000 micrometers. The beads according to the invention advantageously have a number average diameter of between 200 and 800 micrometers, and advantageously between 300 and 700 micrometers. According to one variant, the balls according to the invention have a number average diameter of preferably between 100 and 500 micrometers, and preferably between 200 and 500 micrometers. The measurement of the average diameter by number of the balls according to the invention is carried out by preferably by optical microscopy according to the following method: The number average diameter, the standard deviation and the coefficient of variation of a population of microbeads are measured using an inverted light microscope, for example OLYMPUS brand, model CKX41 and equipped with a camera and a 20X objective. A fraction of the population of microbeads is placed in an observation cup itself placed under the objective. A digital picture is taken after adjusting the picture. The program "LABSENSE" brand OLYMPUS and accompanying the microscope allows tracing straight lines calibrated according to the lens used. A minimum of 20 balls is selected on the image and a diagonal is drawn by the program on each of them. The program allows direct visualization of the measurement. These measurements are reported on a spreadsheet, for example EXCEL of the MICROSOFT brand, and the following variables are calculated. The average is calculated using the formula: s = - The standard deviation is calculated using the formula: The coefficient of variation C, is calculated using the formula (divided standard deviation) averaged): "n" represents the number of balls in the sample whose diameter is measured, "x," represents the diameter measured for a ball, "i" being an integer ranging from 1 to n. The diameter distribution of the microbeads can also be measured by a laser diffraction method, for example using a Mastersizer equipment from Malvern, for example a Mastersizer 2000, using a preference measurement protocol according to the IS013320 standard. : 2009 or following the monograph of the European Pharmacopoeia EP2.9.31, implementing Mi's theory.
    [0011] Advantageously, the distribution of the balls is narrow, that is to say with a small dispersion of the diameter of the balls relative to the average diameter, that is to say for example a dispersity index of less than 2 measured by diffraction laser, for example as above.
    [0012] Advantageously, the microbeads have a D (0,1) of between 100 and 600 micrometers, and advantageously of between 200 and 400 micrometers. According to one variant, the microbeads have a D (0.5) comprised alternatively between 100 and 800 micrometers, and preferably between 300 and 700 micrometers. Preferably, the microbeads have a D (0.5) ranging from 300 to 600 micrometers. Advantageously, the microspheres have a D (0.9) of between 100 and 1000 micrometers, and advantageously between 300 and 950 micrometers. According to a specific variant, the microspheres have a D (0.9) of between 100 and 950 micrometers, and advantageously between 300 and 900 micrometers, more advantageously between 300 and 800 micrometers. According to a specific variant, the microspheres have a D (0.9) of between 200 and 700 microns, and advantageously between 300 and 650 microns. The invention particularly relates to sterilized or non-sterilized hydrogel beads whose diameter D (0.9) is: less than 700 μm (which can be injected via a 19 gauge needle), less than 650 μm (which can be injected via a needle 20 Gauge), - less than 500pm (can be injected via a 21 Gauge needle). D (0.1), D (0.5) and D (0.9) are measured by laser diffraction as above. Advantageously, the hydrogel microbeads comprise at least 95% water by weight. According to a specific variant, the hydrogel microbeads comprise at least 97% by weight of water. Advantageously, the chitosan is present at a concentration of 0.3 to 10% by weight, and the polyphosphate compound (s) being present in an amount sufficient to form a hydrogel microbead, the percentages by weight being expressed relative to the mass. of the microbead. According to one embodiment, the chitosan is present in the hydrogel at a concentration of between 0.5 and 5%, and preferably between 1.0 and 3% by weight of chitosan, the percentages by weight being expressed relative to the mass of the microbead.
    [0013] Percentages by mass expressed relative to the mass of the hydrogel microbead are expressed relative to the constituents of the hydrogel. The mass percentages expressed relative to the mass of the hydrogel microbead preferably include the active agent-free hydrogel microbead, for example, cells, polypeptides, proteins, polynucleosides or polynucleotides, which have a therapeutic value and are not directly necessary for the preparation of the hydrogel.
    [0014] According to a specific variant, the microbead comprises between 1.0 and 3.0%, and for example 1.5% by weight of chitosan. Chitosan is referenced as CAS No. 9012-76-4. The chitosan of the invention is a polysaccharide preferably prepared from a fungal source. It is preferably extracted and purified from safe and abundant food or biotechnological fungal sources such as Agaricus bisporus or Aspergillus piger. Chitosan is obtained by hydrolysis of an extract rich in chitin. Chitin is a polysaccharide composed of several N-acetyl-D-glucosamine units linked together by a type B (1,4) bond. Chitosan consists of D-glucosamine units (deacetylated units) and N-acetyl-D-glucosamine units (acetylated units) connected to one another by B (1,4) type bonds and constitutes a poly-type polymer. (N-acetyl-D-glucosamine) -poly (D-glucosamine). The chitosan of the invention is therefore advantageously of fungal origin, and preferably derived from the mycelium of a fungus of the Ascomycete type, and in particular Aspergillus piger, and / or a Basidiomycete fungus, and in particular Lentinula 20 edodes (shiitake) and / or Agaricus bisporus. Preferably the fungus is Agaricus bisporus. Any origin and method of preparation of chitosan may be used. A method for preparing chitosan is that described in the patents from application W003068824 (EP1483299, US 7,556,946). Chitosan is advantageously chitosan not chemically modified by a covalent coupling reaction with one or more other chemical species. Chitosan is advantageous for its ability to form particles of three-dimensional structure of the mechanically resistant hydrogel type, its biocompatibility and its biodegradability after administration or implantation. In addition, the presence of chitosan in such hydrogel particles is desired for its intrinsic, physico-chemical and / or biological properties, for example for its ability to adhere to biological surfaces or its ability to stimulate tissue healing. According to one variant, the average molecular weight of chitosan is less than or equal to 80,000. According to one variant, the molecular weight of chitosan is between 15,000 and 70,000, and preferably between 35,000 and 60,000.
    [0015] According to another variant, the average molecular weight of chitosan is greater than 80000. In particular, the molecular weight of chitosan is greater than 140000. The upper limit and in general imposed by the viscosity of the chitosan solution. It is preferred to use a chitosan whose average molecular weight is less than 1,000,000. Preferably, the average molecular weight is the viscosity average molecular weight (Mv), calculated from the intrinsic viscosity according to the Mark-Houwink equation. . The intrinsic viscosity is measured by capillary viscosimetry, with a Ubbelohde capillary viscometer, according to the method of the monograph of the European Pharmacopoeia EP2.2.9. The flow time of the solution is measured through a suitable capillary tube (Lauda, for example the capillary tube Ubbelohde 510 01 with a diameter of 0.53 mm) using a Lauda Visc automatic viscometer, first at the concentration initially in chitosan, then for several dilutions, for example according to the recommendations of method EP2.2.9. The reduced intrinsic viscosity is deduced for each of the concentrations. The reduced viscosity is plotted as a function of temperature, and the value is extrapolated to the concentration 0 to deduce the intrinsic viscosity. For example, the reduced viscosity (hréd in ml / g) of the dilutions as a function of the concentration C of the dilutions (g / ml) according to the formula 5 should be used. Formula 2. [hra] = (t1-t0) - (1 C).
    [0016] To calculate the average viscometric mass, the Mark-Houwink equation is applied with the k and alpha constants recommended by Rinaudo et al. (Int.J. Biol Macromol, 1993, 15, 281-285), according to the AD of chitosan, according to one of the following three formulas. Formula 3. Mv = ([h] / 0.082) (1 / 0.76), for a DA of 2%; Formula 4. Mv = ([h] / 0.076) (1 / ° '76), for a DA of 10% (e.g., 11.5%); Formula 5. Mv = ([h] / 0.074) (1 / ° '76), for a DA of 20% (for example 21%). For the intermediate DA values, a linear interpolation is performed to calculate the average viscometric mass (Mv).
    [0017] By way of example, the chitosan may have a degree of acetylation of between 10 and 40%, and preferably between 10 and 25%. The degree of acetylation is determined by potentiometry. Chitosan is dissolved in a solution of hydrochloric acid. Excess hydrochloric acid unreacted with the amine functions of chitosan is assayed with a standard solution of sodium hydroxide. This gives the number of moles of D-glucosamine unit present in the chitosan and thus by subtraction the degree of acetylation.
    [0018] For example, the chitosan solution at a concentration of 1.5% (w / v) in 1% (v / v) acetic acid can have a dynamic viscosity of between 100 and 500mPa.s. Advantageously, the chitosan of the present invention may have a dynamic viscosity of between 50 and 400 mPa.s in a 1.5% solution.
    [0019] The dynamic viscosity of the 1.5% (w / v) chitosan solution is preferably between 150 and 300mPa.s, and more preferably between 200 and 280mPa.s. The viscosity is typically measured by rotating mobile viscometry, for example on a Brookfield DV2T device at a rotation speed of 5 rpm with a Spindle SC4-18 needle at 25 ° C.
    [0020] The polyphosphate compound is preferably a salt of an organic or inorganic polyphosphate compound. Examples of organic polyphosphate compounds that may be mentioned include phytic acid, in particular sodium inositol hexakisphosphate, or a glycerophosphate, for example sodium beta-glycerophosphate.
    [0021] Examples of inorganic polyphosphate compounds are tripolyphosphate, in particular sodium tripolyphosphate. Advantageously, the polyphosphate compound is chosen from phytic acid, such as, for example, sodium phytic acid, a tripolyphosphate, for example sodium tripolyphosphate, a glycerophosphate, for example a sodium beta-glycerophosphate, and any of their mixtures. Phytic acid or hexaphosphoric myo-inositol acid or also hexakisphosphoric acid inositol is a biomolecule of formula C61-118024P6. Phytic acid is a compound of ubiquitous plants, present at 1-5% by mass of most cereals, nuts, seed oil, spores, and pollens. It typically represents a proportion of 60 to 90% of the phosphorus duotal of the seeds. It is found as a mixture of salts, typically calcium / magnesium and potassium in some parts of the seeds. This molecule is highly charged with the six phosphate groups extending from the center of the myo-ionisol nucleus, with each group having its own pKa. The properties of phytic acid can be found, for example, in article 30 of Evans et al. (Titration Studies of Phytic Acid, JAOCS, 59, 4, 1982). For example, phytic acid is present in the hydrogel of microbeads at a concentration of 0.5 to 10% by weight. According to a specific variant, the phytic acid is present in the hydrogel at a concentration of at least 1%, and preferably at least 2% by weight of phytic acid.
    [0022] According to a specific variant, the microbead comprises between 2% to 10% and more particularly from 4% to 8% by weight of phytic acid.
    [0023] Advantageously, the present invention relates to a microbead comprising 1 to 2% of chitosan and at least 3% by weight of phytic acid. An exemplary composition of the microbead comprises 1.5% of chitosan and 4 to 8% of phytic acid in mass relative to the mass of the total composition of the microbead. between 0.5% to 5% and more particularly 1% to 5% by weight of tripolyphosphate, preferably of sodium tripolyphosphate Advantageously, the present invention relates to a microbead comprising from 1.10% to 1% of chitosan and at least 0.5% by weight. of tripolyphosphate, preferably sodium tripolyphosphate An example of composition of the microbead comprises 1.5% of chitosan and 1 to 2% of tripolyphosphate, preferably of sodium tripolyphosphate, in mass relative to the mass of the total composition of the microbead.
    [0024] According to a specific variant, the microbead comprises between 2% to 10% and more particularly from 4% to 8% by weight of glycerophosphate, preferably sodium betaglycerophosphate. Advantageously, the present invention relates to a microbead comprising 1 to 2% of chitosan and at least 3% by weight of glycerophosphate, preferably a sodium beta-glycerolphosphate. An exemplary composition of the microbead comprises 1.5% of chitosan and 4 to 8% of glycerophosphate, preferably a sodium beta-glycerophosphate in mass relative to the mass of the total composition of the microbead. Advantageously, the microbead comprises a sufficient amount of base to raise the pH to a level allowing the formation of hydrogel microbeads of the invention. Among the bases that may be mentioned are mineral bases such as, for example, sodium hydroxide, sodium carbonate, potassium hydroxide and the like. After washing with successive baths of water, the microbead contains water, chitosan and the polyphosphate compound.
    [0025] In addition to water, chitosan, the polyphosphate compound, the microbead of the present invention may comprise different excipients and / or different active ingredients. Among the excipients, mention may be made of the agents promoting the gelling of the bead, the agents for modifying the viscosity, the agents for modifying the rheology, and agents for modifying the kinetics of degradation of the microbeads in vivo, etc.
    [0026] The composition of the microbeads is advantageously non-thermogelifiable. Indeed, to ensure good stability of the beads before and after injection, typically by the intra-articular route, the gelation or sol-gel transition should not occur after or at the time of injection. Advantageously, the microbeads of the invention are in hydrogel form before their application, in particular by injection into the body of a subject in need, in particular at the intra-articular level. In particular, the microbeads are in hydrogel form during storage, for example at room temperature or in the cold, and are not sensitive to temperature variations between 8 and 40 ° C, ie they are not disintegrated or degraded in this temperature range. In this regard, the microbeads may be suspended in a viscous solution or a hydrogel, which, advantageously, may be thermally gelable. This is typically a hydrogel of one or more gelable polysaccharides. The present invention also relates to a viscous solution or a hydrogel, thermogelifiable or not, comprising a plurality of microbeads of the invention. The composition of the microbead according to the invention may also comprise compounds of interest, particularly at the pharmaceutical level (active pharmaceutical ingredient) and even more specifically for an intra-articular action, more particularly on cartilage. It is even more specifically beneficial agents in compositions for intra-articular use, for example to reduce pain or decrease inflammation. Such agents include anti-inflammatory drugs, more particularly non-steroidal drugs, anesthetic agents, analgesic agents, in particular of the opioid type, corticosteroids, anti-neoplastics, monoclonal antibodies, vitamins, minerals, contrast agents, etc. Non-steroidal drugs (NSAIDS) may for example be mentioned for example: Diclofenac ™, Ibuprofen ™, Piroxicam ™; anesthetics, for example: Lidocaine ™, Bupivacaine ™; opioid analgesics for example: codeine, morphine; corticosteroids, for example: dexamethasone, prednisone; antineoplastic agents, for example: MethotrexateTM; antiviral agents, for example: AcyclovirTM, VidarabineTM; monoclonal antibodies, for example: Humira ™ Infliximab ™ The microbeads of the invention, in particular usable as intra-articular injectable supplements may also contain compounds such as cells, proteins, polynucleotides (RNA, DNA), minerals as for example: selenium, strontium, vitamins such as: tocopherol, or other active agents such as curcumin.
    [0027] Among the cells, it is particularly advantageous to use chondrocytes, stem cells, or cells having the capacity to produce active substances. The hydrogel microbeads according to the present invention have a homogeneous hydrogel structure. The hydrogel microbeads according to the present invention do not have trabeculae or solid particles inherent in the preparation of the hydrogel. It is not excluded that active agents are in solid or colloidal form, for example in nanoparticulate form. Advantageously, the microbeads of the invention are cohesive. The cohesion of the 10 balls is not lost during the friction between the hands. In addition, the beads advantageously have good compressive strength, especially when handling between the fingers. Such a resistance can be evaluated, for example, by measuring the compressive strength of a mechanical compression bench (for example an Instron Bluehill equipment). It is also possible to use a nanoindentation technique (for example with the PI Series Picoindenter range of equipment marketed by Hysitron or the Mach 1 marketed by Biomomentum) or else a suitable tribology technique (for example with range of Tl Series Triboindenteur equipment marketed by Hysitron).
    [0028] Advantageously, the balls are deformable and can be injected by a needle into the inner diameter is smaller than the maximum diameter of the balls. This has a great advantage for injection into a tissue because with equal inner diameter, a smaller outside diameter needle can be used, thus forming a smaller diameter hole.
    [0029] The microbeads can advantageously be manufactured according to the method of the invention. The invention therefore relates to a process for the preparation of hydrogel microbeads according to the invention. More specifically, the process of the invention comprises adding a solution of chitosan to a crosslinking solution comprising at least one polyphosphate compound and then gelling the chitosan in the presence of the crosslinking solution to form the microbeads. hydrogel. The chitosan is preferably dissolved in an aqueous solution at pH below 7. Such a solution typically comprises an acid, preferably a weak one, such as, for example, an organic acid. It is advantageous to use acetic acid. The solution typically comprises 0.5 to 3% of acetic acid expressed in volume relative to the total volume of the chitosan solution. The pH of the chitosan solution is typically between 2 and 6.5, and preferably between 3.5 and 6.0.
    [0030] Advantageously, the osmolarity of the chitosan solution at a concentration of 1.5% (w / v) ranges from 100 to 300 mOsm / kg, at a temperature of 25 ° C. The determination of the osmolarity of the solutions is carried out with an automatic micro-osmometer (Osmometer Type 15M from Leiser Messtechnik). The equipment is calibrated beforehand with a solution of 300mosm / kg. Sample 10 is placed in a container provided for this purpose, and is brought to the standard temperature of the measurement. The gelling of the droplets of the chitosan solution in the form of microbeads takes place under conditions suitable for gelling the chitosan solution and the polyphosphate compound.
    [0031] Alternatively, one or more polyphosphate compounds may be added to the chitosan solution before this solution is dripped into the crosslinking solution comprising one or more polyphosphate compounds identical or different from the one (s) added to the chitosan solution. For example, from 0.01 to 1% (w / w), and preferably from 0.1 to 0.5% (w / w, meaning mass / mass), of polyphosphate compound can be added to the solution of chitosan. According to one variant, the crosslinking solution has a pH of between 8 and 14, more particularly between 9.5 and 14, adjusted by adding a dilute solution of a base, for example sodium hydroxide. According to one variant, the crosslinking solution is a solution of phytic acid and of sodium hydroxide having a pH of between 5.5 and 7, for example of approximately 6. According to one variant, the crosslinking solution is a solution of phytic acid and sodium hydroxide having a pH of between 8 and 14. According to another specific variant, the crosslinking solution is a solution of phytic acid and sodium hydroxide having a pH of between 8 and 10, for example about 9. According to another specific variant, the crosslinking solution is a solution of phytic acid and sodium hydroxide having a pH of between 11 and 14, for example about 13. Advantageously It is possible to vary the properties of the hydrogel microbeads according to the pH of the crosslinking solution used.
    [0032] The base concentration in the crosslinking solution is determined by those skilled in the art in order to obtain the desired pH. A base concentration of from 0.01 to 1 M, and more specifically from 0.05 to 0.75 M, can typically be used in the crosslinking solution.
    [0033] Gelation is carried out by contacting the chitosan solution dropwise with a crosslinking solution comprising at least one polyphosphate compound, or optionally one or more other gelling agents. The device for the formation of the drops and their gelation may be of the "prilling" type, that is to say a grilling process. Preferably, a device 10 comprising a drop-producing nozzle having an internal diameter greater than or equal to 100 can be used, for example using a diameter of 100 or 150 μm. For the formation of microbeads, a batch process may be used, for example by passing the solution through a needle using a peristaltic pump. It is also possible to use a continuous, industrially appropriate process. By way of example of a continuous process, for example, an electromagnetic laminar jet process, also known as prilling, as with the VAR-D continuous equipment (marketed by Nisco), for example, was used. formation of electrostatic drops, or coaxial air flow, or dynamic air flow, or by gravity, or by spray (or "spray drying"), or by continuous extrusion 20 with the outgoing jet cut to the using a rotary tool (called Jetcutter, as with Genialab equipment). When the droplets of chitosan solution fall into the crosslinking solution comprising the polyphosphate compound, stirring can be carried out, for example using a magnetic bar, for example a speed of between 50 and 500 rpm.
    [0034] Advantageously, the process comprises washing the microbeads, preferably with an aqueous solution, and still more preferably water. Intensive washing is preferably carried out under conditions capable of obtaining hydrogel microbeads of constant diameter from one wash to another. The process of the invention comprises, for example, the recovery of microbeads 30 by gravity. When agitation is stopped, the beads settle to the bottom of the container containing the solution, typically the washing bath container. For example, the solution can be removed by a suction device, such as through a needle whose characteristics (typically the diameter) do not allow the passage of microbeads. After removal of the solution, only the microbeads remaining in the container remain, which can be manipulated for subsequent operations.
    [0035] The present invention also relates to sterile microbeads. Advantageously, the microbeads are sterilized with moist heat, typically using an autoclave. Typically, the autoclave conditions are a temperature of about 121 ° C for a duration of at least 15 minutes.
    [0036] Thus, the present invention further relates to a method of sterilizing the microbeads described in the invention. The present invention relates to a pharmaceutical composition or a medical device comprising a plurality of microbeads according to the invention or obtained according to the method of the invention.
    [0037] The present invention also relates to an injectable pharmaceutical composition comprising the microbeads of the invention. The present invention relates to a pharmaceutical composition or a medical device consisting of an artificial synovial fluid. According to one variant, the pharmaceutical composition or the medical device is useful in the treatment of a pathology of a joint. Alternatively, the pharmaceutical composition or medical device is useful in the treatment of pain or discomfort associated with a pathology affecting a joint or to slow the progression of a pathology of a joint. The present invention also relates to a medical device, possibly in the form of one or more packaging kits, possibly physically separated, comprising a syringe, a needle and a pharmaceutical composition or medical device according to the invention, said syringe comprising a reservoir optionally pre-filled with the pharmaceutical composition or medical device mentioned above. The present invention relates to such a medical device for its use in the treatment of a joint pathology comprising the injection of a pharmaceutical composition or medical device according to the invention intra-articularly. The present invention also relates to hydrogel microbeads according to the invention, or obtained according to the invention for its use in the treatment of a pathology, by injection into the human or animal body, optionally the presence of a solution or hydrogel injectable. For example, the needle used is a needle selected from 18 to 22 gauge needles, more preferably 22 gauge and larger. For example, the needle used has normal walls, thin or extra-fine. The present invention further relates to a method of supplementing the synovial fluid, particularly in a condition affecting a joint, such as osteoarthritis (osteoarthritis or osteoarthritis) or cartilage lesions, etc.
    [0038] The present invention further relates to a method of combating pain or discomfort associated with a condition affecting a joint. The present invention further relates to a method of controlling inflammation of a joint.
    [0039] More specifically, such pathologies are for example: osteoarthritis (osteoarthritis) (primary (idiopathic) or secondary), rheumatoid arthritis (rheumatoid arthritis), injury of a joint (for example traumatic or an injury to the repeated joint mobility), cartilage pathology (eg, chondrocalcinosis or chondromalacia), septic arthritis.
    [0040] The present invention further relates to a method of reducing or combating the pain associated with a disease, for example as those mentioned above, or to slowing its progression. The present invention further relates to a method for improving bone repair, particularly cartilage.
    [0041] Such methods typically include intra-articular injection of a composition comprising microbeads according to the invention. According to a variant, the method according to the invention comprises a plurality of injections. According to one variant, an injection can be made once or twice a month for several months. According to another variant, two injections spaced apart from a variable time are carried out. According to another variant, a single injection is made. The methods of the invention are useful for a subject in need, such as for example a subject requiring the treatment of an articular pathology. The injection site (s) are typically selected from: knee, shoulder, hip, temporomandibular joint, carpometacarpal joint, elbow, ankle, wrist, hand joint, intervertebral disc, or other joint. According to a variant, the injection is performed in an articular cavity, in contact with the cartilage. When the microbeads are added to a fluid, a viscous solution or a hydrogel, for example to a viscosupplement, for example comprising a hyaluronic acid, an increase in modulus of elasticity (G ') measured by rheology is obtained. This reflects the stress resistance of the hydrogel microbeads, and hence an improvement in the stress resistance of the fluid containing the microbeads. By extension, the ability of the fluid to absorb shock, for example when injected into a joint and more specifically the knee joint, is improved in the presence of the beads. The viscosity of the fluid at physiological temperature is advantageously unchanged, so that it remains easy to inject through a physician-acceptable needle diameter and maintains a viscosity sufficient to act as a viscosupplement. Thus, the present invention also relates to the use of microbeads according to the invention, or obtained according to the invention, for modifying the properties, in particular the mechanical properties, of a viscosupplement, for example injectable at a joint . More generally, the microbeads of the invention are used in tissue engineering or as vectors of active compounds, in particular as vectors of pharmaceutically active compounds.
    [0042] Expressions of the type "comprises from ... to ..." "from ... to ..." "from ... to ..." or their equivalents include the above-mentioned terminals, unless otherwise indicated. According to one variant, the limits of the interval are excluded. "Composition according to the invention" or equivalent terms means a defined composition, method or process as in the present invention, including any of the variants, particular or specific embodiments, independently or according to the invention. any of their combinations, including according to the preferred features. In the figures: FIG. 1 shows an optical microscope observation of the hydrogel microbeads formed in the presence of the crosslinking solution containing sodium betaglycerophosphate at the 5% concentration and the sodium hydroxide at the concentration 0, 1M (No. 7). FIG. 2 shows an optical microscope observation of hydrogel microbeads formed in the presence of the cross-linking solution containing sodium tripolyphosphate at the concentration of 2%, sodium glycerophosphate at the concentration of 5% and the sodium hydroxide. sodium at the concentration of 0.1M (No. 8). Other objects, features and advantages of the invention will become apparent to those skilled in the art from the reading of the explanatory description which refers to examples which are given by way of illustration only and which can not in no way limit the scope of the invention. The examples are an integral part of the present invention and any features appearing novel from any prior art from the description taken as a whole, including the examples, form an integral part of the invention in its function and function. in its generality. Thus, each example has a general scope.
    [0043] On the other hand, in the examples, all percentages are given by weight, unless otherwise indicated, and the temperature is expressed in degrees Celsius unless otherwise indicated, and the pressure is atmospheric pressure unless otherwise indicated.
    [0044] Examples Table 1 - References for needle sizes for microbead injection according to ISO 9626 (1991: Amd 1: 2001) Source Gauge Diameter Internal Diameter (ID) OD (min - max) ( pm) Wall ID Wall ID Wall ID normal / regular Fine / fine extra- (11m) (pm) fine / ultrafine (11m) 1 29 324 - 351 133 190 27 400 - 420 184 241 26 440 - 470 232 292 25 500 - 530 232 292 22 698 - 730 390 440 522 20 860 - 920 560 635 687 19 1030 -1100 648 750 850 18 1200 -1300 790 910 1041 2 23 -620 -325 21 -820 -500 1- "The Gauge system for the medical use "in Anesthesia & Analgesia, 2002; the 10 values are taken from IS09626: 1991 / Amd 1: 2001. 2- "Does needle size matter ", In J Diab Sci Technol 1, 725, 2007. The outer diameter (OD) (min - max) denotes the tolerance according to the aforementioned standard. Unless otherwise indicated, the internal diameter of the needles mentioned is normal / regular walls. EXAMPLE 1 Preparation of the chitosan solution An ultrapure chitosan of fungal source (Synolyne Pharma, Belgium), with a mean viscosimetric molecular mass (Mv) of 180,000 (greater than 140,000) and 3029,790 acetylation degree (DA) of 27 molar ° / 0 (greater than 20 mol%) is dispersed in a solution containing 1% (0.167M) of acetic acid, at a concentration of 1.5% (between 1 and 2%) with magnetic or mechanical stirring. The solution is mixed for a period of 3 hours (1 to 12 hours). The solution is filtered on a filter with a pore diameter of 511m. At a concentration of 1.5%, the pH of the chitosan solution is about 4, its osmolarity at 25 ° C is about 150mOsm / kg, and its dynamic viscosity is about 220mPa.s (measured by viscosimetry to mobile rotating with Brookfield equipment, at 5 rpm with Spindle SC4-18).
    [0045] Droplets from this chitosan solution can be formed with small diameter nozzles up to the smallest size available for the VAR-D (Nisco) equipment, ie with the 100pm diameter nozzle. EXAMPLE 2 Preparation of Polyphosphate Compound-Based Crosslinking Solutions Crosslinking solutions are mixtures of polyphosphate compounds alone or in combination at different concentrations, the pH of which is adjusted in the presence of a base such as, for example, sodium hydroxide , or not. The polyphosphate used is a compound chosen from: sodium tripolyphosphate (TPP, Sigma), sodium betaglycerophosphate (GP, Safic Alcan), or phytic acid in the form of sodium salt anhydride (or inositol hexakisphosphate) anhydrous sodium, PA, Sigma). The concentrations of the polyphosphate compounds and the base (NaOH) as well as the pH of the crosslinking solutions are shown in Table 2.
    [0046] Table 2 - Polyphosphate Compound-Based Crosslinking Solutions No. Polyphosphate NaOH pH Feasibility of Stable Hydrogel Microbead Preparation (Examples 3 and 4) 0.05M 12.8 No 0.2 0.1 M 13.0 No 3 0 0.5M 13.2 No 4 TPP 5% 0 8.6 No 5 GP 5`) / 0 0 9.3 No 6a TPP 5% 0.1M 12.9 Yes 6b TPP 2.5% 0 , 05M 12.4 No 6c TPP 1.25% 0.075M 12.7 Yes 7 GP 5% 0.1M 13.0 Yes 8a * TPP 2% and GP 5% OM 8.8 Not 8b ** TPP 2% and GP 5 % 0.05M 12.5 Yes 8c TPP 2% and GP 5% 0.1M 12.9 Yes 9 PA 5`) / 0 0 3.0 No 10 PA 5`) / 0 0.1M 6.0 Yes 11 PA 5`) / 0 0.3M 9.0 Yes 12 PA 5`) / 0 0.5M 13.0 Yes 13 PA 2`) / 0 0.1 M 6.0 No 14 PA 2% 0.3 M 9.0 No 15 PA 2% 0.5 M 13.0 No * 8a: TPP 2% + GP 5% without NaOH => the beads are formed but are unstable: they crumble after 5 to 10 minutes: the balls are not in accordance with the microbeads of the invention; ** 8b: TPP 2% + GP 5% + NaOH 0.05M => the beads are formed and remain stable after one hour in the crosslinking solution: the beads are in accordance with the invention 10 3029790 21 Example 3 - Preparation of microbeads of chitosan hydrogel by cross-linking with tripolyphosphate (TPP) alone or in combination with glycerophosphate (GP) Droplets are formed from the chitosan solution according to Example 1 by an electromagnetic method with equipment "Encapsulator VarD" (Gen 2) (Nisco, Zürich, Switzerland), equipped with a nozzle with a diameter of 150 pm The droplets are immersed in a volume of 50 ml of one of the crosslinking solutions according to Example 2 (Nos. 1 to 8c of Table 1). 1), and are stirred for 3 hours with the aid of a magnetic bar, at a speed of between 100 and 1000 rpm.When microbeads are formed, they are then washed with water ( about one liter each wash) several times in con Sequential stirring is carried out with a magnetic bar for about one minute between each wash, at a speed of between 100 and 1000 rpm. The beads are allowed to settle between each wash. The balls are finally recovered by gravity. A container containing a known mass of hydrogel beads as well as a known mass of water is obtained. It emerges from this example that stable hydrogel beads can be formed in the presence of crosslinking solutions No. 6, 6c, 7 and 8c, that is to say only in the presence of polyphosphate salts TPP and / or GP and a sufficient amount of NaOH.
    [0047] The stable hydrogel beads can not be formed in the presence of NaOH alone (Nos. 1 to 3), in the absence of polyphosphate: at these pHs the chitosan precipitates, no dots are formed. stable hydrogel. In the presence of polyphosphate TPP and / or GP and in the absence of NaOH, the beads formed are not sufficiently stable from a mechanical point of view, and are not resistant to successive washes.
    [0048] The conditions of the crosslinking solution which give the best results in terms of cohesion and stability of the hydrogel microbeads are the conditions Nos. 6c, 7 and 8c. The characteristics of the hydrogel beads thus obtained are summarized in Table 3.
    [0049] Table 3 - Characteristics of the hydrogel microbeads formed in the presence of GP and a GP / TPP mixture in the presence of NaOH (150 μm diameter nozzle) Diameter Distribution Solution Appearance and crosslinking behavior of the mechanical hydrogel beads By microscopy By laser optical diffraction No. 6c ND D (0.1) = 190pm Good withstand TPP 1.25% NaOH 0.075M pH = 12.7 D (0.5) = 490pm D (0.9) = 740pm No. i average diameter = 645pm diameter min = 370pm max diameter = 890pm ND Insoluble balls, GP 5`) / 0 elastic, 0.1M NaOH pH = 13.0 moderately round (Figure 1) No. 8c average diameter = 560 lm min diameter = 420pm max diameter = 700pm ND More resistant beads, GP 5`) / 0 TPP 2c) / 0 0.1M NaOH pH = 12.9 less elastic, rounder (Figure 2) ND: Not determined In Figures 1 and 2 the substantially spherical shape is observed hydrogel microbeads of the invention. It is concluded from this example that it is necessary to reach a sufficiently high pH to obtain hydrogel beads of good stability and integrity and well elastic with TPP and GP polyphosphates. It is also concluded that the hydrogel beads formed by contact with the TPP and GP solution in combination are more stable and elastic than the beads formed from TPP or GP alone at equivalent basic pH. It is also possible to produce stable hydrogel microbeads of smaller size with the 100 μm diameter nozzle. The microbeads of the invention are injectable through fine needles.
    [0050] EXAMPLE 4 Preparation of Chitosan Hydrogel Microbeads with Phytic Acid Droplets were formed from the chitosan solution according to Example 1 by an electromagnetic method with a "Encapsulator VarD (Gen 2)" equipment. (Nisco, Zürich, Switzerland), equipped with a 100 μm diameter nozzle The droplets are immersed in a volume of 50 ml of one of the phytic acid (PA) based crosslinking solutions according to Example 2 (No. 9 to 15 of Table 1), and are stirred for 3 hours with a magnetic bar at a speed of between 100 and 1000 rpm, when microbeads are formed, they are then washed at the water (approximately one liter each wash) several times consecutively.A slight stirring with a magnetic bar is carried out for about a minute between each washing, at a speed of between 100 and 1000 rpm. sediment between 15 ch The balls are finally recovered by gravity. A container containing a known mass of hydrogel beads as well as a known mass of water is obtained. It emerges from this example that stable hydrogel beads can be formed in the presence of the crosslinking solutions No. 10, 11 and 12, that is to say only in the presence of polyphosphate PA and NaOH simultaneously, the two components both must be in sufficient quantity. The characteristics of the hydrogel beads thus obtained are summarized in Table 4. In the presence of phytic acid at a concentration of 5% and in the absence of NaOH, the beads formed are not stable over time, and not not resist successive washings with water. When NaOH is added, stable beads are formed at the concentration of 0.1M NaOH (pH 6.0), unlike the TPP and GP polyphosphates of Example 3, for which the pH must be higher ( for example, higher than 12.5) for the beads to be stable. In the presence of phytic acid at a lower concentration of 2% irrespective of the amount of NaOH (from 0.1 to 0.5M), beads are formed, but they are not stable.
    [0051] Table 4 - Characteristics of hydrogel microbeads formed in the presence of phytic acid and NaOH Solution of Diameter Distribution Appearance and carrying capacity crosslinking of hydrogel beads (before sterilization) mechanical beads By optical microscopy No. 1C Average diameter = 325um Opaque PA 5% Min diameter = 260um Soft, deformable, 0.1M NaOH pH = 6.0 Max diameter = 360um elastic and soft N ° 11 Number average diameter between Transparent with PA 5 ° / 0 100 and 700 lm opaque core 0.3M NaOH pH = 9.0 Moderately elastic, moderately hard N ° 12 Number average diameter between Very transparent, PA 5 ° / 0 100 and 700 lm with a very 0.5M NaOH core pH = 13 , 0 dense and of small diameter Little deformable and elastic, hard Diameter min / max: Smallest / largest diameter measured among the 20 balls observed. It is concluded that with a sufficient amount of phytic acid (eg 5%) and in the presence of NaOH, hydrogel microbeads can be formed irrespective of the NaOH concentration and the pH (above 6, 0). On the other hand, the proportion of NaOH strongly influences the appearance and the mechanical strength of the hydrogel beads. It is thus possible to modulate the properties of the microbeads.
    [0052] The beads are sterilized with moist heat (autoclave - model SYSTEC DX-23, Wettenberg, Germany). The autoclaving parameters are as follows: temperature of 121 ° C, duration of 15 minutes.
    [0053] The microbeads thus sterilized have a number average diameter of between 100 and 700 μm. Specifically, the beads prepared using the crosslinking solution No. 10 have a mean diameter of 200 μm in romumbia.
    [0054] They are injectable through fine needles.
    [0055] EXAMPLE 5 - Rheological properties When the microbeads according to Examples 3 and 4 are added to a fluid, a viscous solution or a hydrogel, for example to a viscosupplement based on hyaluronic acid, an increase in the modulus of elasticity is obtained. (G ') measured by rheology (detail of the method). This reflects the stress resistance of the hydrogel microbeads, and hence an improvement in the stress resistance of the fluid containing the microbeads. By extension, the ability of the fluid to absorb shocks, for example when it is injected into a joint and more specifically the knee joint, is improved in the presence of the balls. The viscosity of the fluid at physiological temperature is advantageously unchanged, so that it remains easy to inject through a physician-acceptable diameter needle and maintains a viscosity sufficient to act as a viscosupplement. EXAMPLE 6 Elasticity of the Microbeads In order to determine the elastic and absorption properties of the hydrogel microbeads, the microbeads - prepared according to Examples 3 and 4 with the crosslinking solutions Nos. 6a, 6c, 8b, 8c, are added. 10, 11 and 12 of Example 2 - to a viscous fluid, for example a solution of hyaluronic acid, at 37 ° C.
    [0056] The rheological properties are measured by oscillating the viscous fluid alone and the viscous fluid with the microbeads, using a rotary rheometer with shearing plates (ARES G2, TA Instrument). This analysis can provide information on the evolution of the variables G ', G "and Tan (15) over a given shear frequency range, for example from 0.1 Hz to 100 rad.s-1, and at a given temperature, for example 37 ° C.
    [0057] The amplitude is fixed in constant value, for example 1%. It is demonstrated that the elastic modulus (G ', also called storage module) of the viscous solution comprising the microbeads is significantly greater than the modulus G' of the solution of the viscous solution without the microbeads, and this 3029790 26 whatever the composition of the crosslinking solution. The difference in G 'is indicative of the elasticity of the microbeads. The value of the modulus G 'of the fluid is significantly increased in the presence of the microbeads, which indicates that the microbeads give the fluid a better ability to withstand stress and absorb shock.
    [0058] In parallel, the dynamic viscosity of the viscous solution with and without the microbeads is measured at 37 ° C. using the same rheometer equipment, under continuous rotation, at increasing speed over a given shear range. It is observed that the dynamic viscosity of the viscous fluid is not modified by the addition of microbeads. It thus remains easily injectable through a needle, and may for example act as a viscosupplement to relieve a joint after injection into the knee joint. For example, a mixture of a viscosupplement (based on hyaluronic acid) commercially available (SynVisc®, Sanofi) is prepared with the microbeads prepared according to Example 3 with the crosslinking solution No. 10 (phytic acid 5%, Na0H0.1M, pH6). Both solutions (with and without microbeads) contain the same concentration of hyaluronic acid. The modulus of elasticity G 'and the dynamic viscosity of the two solutions are measured at 37 ° C., according to the measurement parameters recorded in Tables 5 and 6. The results are shown in Tables 5 and 6. It follows from this example That the addition of chitosan and phytic acid microbeads results in an increase in the modulus of elasticity of the hyaluronic acid solution of 40%, without modification of its dynamic viscosity. The microbeads are easily injectable through a needle of variable diameter, and in particular a needle adapted to intra-articular injection. The microbeads of the invention harvested after injection retain substantially the same size distribution. Moreover, the same hyaluronic acid solution with the microbeads (obtained with solution No. 10 of Table 3) is injectable through needles of variable diameter, for example a needle adapted to intra-articular injection. The beads harvested after injection retain substantially the same size distribution.
    [0059] Table 5 - Modulus of elasticity G 'of a commercial hyaluronic acid with and without microbeads (No. 10), at 37 ° C. Oscillation frequency (Hz) G'HA Without microbeads (Pa) G' HA + MB With microbeads (Pa) Difference G'HA + MB - G'HA (Pa) Difference (G'HA + MB-G'HA) / G'HAX100 (%) 1 25 35 10 + 40% 10 66 93 27 + 41% Table 6 - Dynamic viscosity of a commercial hyaluronic acid with and without microbeads (No. 10), at 37 ° C. Dynamic Viscosity Rate HA without dynamic Viscosity HA with shear (per second) microbeads (mPa · $) microbeads ( mPa. $) 1 32 33 10 3.7 3.7 HA: Hyaluronic acid; 5 MB: Microbead Example 6 - Stability of the beads during storage and injectability The hydrogel microbeads prepared using the crosslinking solutions Nos. 6a, 6c, 8b, 8c, 10, 11 and 12 of Example 2 are preserved. at 4 ° C in an aqueous solution.
    [0060] After a storage period of 3 and 6 months, their appearance, number average diameter and size distribution, measured according to the methods of the description, are unchanged. The microbeads are injectable without difficulty through a thin needle, and substantially retain their size characteristics after injection.
    权利要求:
    Claims (15)
    [0001]
    CLAIMS1.- Hydrogel microbead comprising at least water, chitosan, at least one polyphosphate compound, the water being present at a concentration of at least 85% by weight, of hydrogel, said microbead having a diameter average in number ranging from 100 to 900
    [0002]
    2. hydrogel microbead according to claim 1, characterized in that the D (0.9) is between 100 and 950 micrometers.
    [0003]
    3.- hydrogel microbead according to claim 1 or 2, characterized in that the chitosan is present at a concentration of 0.3 to 10% by weight, and the polyphosphate compound (s) being present in an amount sufficient to form a hydrogel microbead, the percentages by mass being expressed relative to the mass of the microbead.
    [0004]
    4.- hydrogel microbead according to claims 1 to 3, micrometers characterized in that the chitosan is present in the hydrogel at a concentration between 0.5 and 5%, and preferably between 1.0 and 3% in mass of chitosan, the percentages by mass being expressed relative to the mass of the microbead.
    [0005]
    5.- hydrogel microbead according to claims 1 to 4, characterized in that the polyphosphate compound is selected from phytic acid, such as for example phytic acid sodium salt, a tripolyphosphate, such as tripolyphosphate, sodium, a glycerophosphate such as sodium beta-glycerophosphate, and any of their mixtures.
    [0006]
    6. hydrogel microbead according to claims 1 to 5, characterized in that it is sterilized.
    [0007]
    7. A process for the preparation of hydrogel microbeads as defined in any one of claims 1 to 6.
    [0008]
    8. A process according to claim 7, characterized in that it comprises the addition of a solution of chitosan to a crosslinking solution comprising at least one polyphosphate compound, and then the gelling of chitosan in the presence of the solution. crosslinking to form the hydrogel microbeads.
    [0009]
    9. A pharmaceutical composition or medical device comprising a plurality of microbeads as defined in any one of claims 1 to 6, or obtained according to any one of claims 7 to 8.
    [0010]
    10.- pharmaceutical composition or medical device according to claim 9, characterized in that it consists of an artificial synovial fluid. 10
    [0011]
    11.- pharmaceutical composition or medical device according to claim 9 or 10 for its use in the treatment of a pathology of a joint.
    [0012]
    12. A pharmaceutical composition or medical device according to claim 9 or 10 for its use in the treatment of pain or discomfort associated with a pathology affecting a joint or to slow the progression of a pathology of a joint.
    [0013]
    13.- Medical device, optionally in the form of one or more packaging kits 20, possibly physically separated, comprising a syringe, a needle and a pharmaceutical composition or medical device according to any one of claims 9 to 12, said syringe comprising an optionally pre-filled reservoir of the aforementioned pharmaceutical composition or medical device. 25
    [0014]
    14. Medical device according to claim 13 for its use in the treatment of a joint pathology comprising injecting a pharmaceutical composition or medical device according to any one of claims 9 to 12 intra-articularly. 30
    [0015]
    15.- Use of microbeads as defined in any one of claims 1 to 6, or obtained according to any one of claims 7 to 8 to modify the properties, in particular the mechanical properties, of a viscosupplement for example injectable at the level of an articulation. 35
    类似技术:
    公开号 | 公开日 | 专利标题
    FR3029790A1|2016-06-17|CHITOSAN HYDROGEL MICROBELL
    Sachan et al.2009|Sodium alginate: the wonder polymer for controlled drug delivery
    CA2708023C|2017-10-03|Biodegradable single-phase cohesive hydrogel
    JP5208332B2|2013-06-12|Intra-joint replacement for treating joint diseases and joint damage
    EP3156059B1|2018-06-06|Sterilised thermogelling composition
    CN102219938A|2011-10-19|Preparation method of hydrophobically modified sodium alginate
    CA2857946C|2020-11-03|Homogeneous aqueous solution of injectable chitosan
    CA2956789A1|2016-02-04|Thermogelling composition
    CA2932967A1|2015-07-02|Hyaluronic acid compositions including mepivacaine
    Karabiyik Acar et al.2018|Hyaluronic acid/chitosan coacervate-based scaffolds
    FR3029422A1|2016-06-10|HYDROGEL MICROBALL
    CA2493470C|2012-05-22|Particles which are surface coated with hyaluronan or one of the derivatives thereof and the use of same as biological vectors for active substances
    WO2017009346A1|2017-01-19|Chitosan for mixing with a coagulable fluid
    WO2017009335A1|2017-01-19|Chitosan for mixing with a coagulable fluid
    CA2926169A1|2015-02-12|Continuous release compositions made from hyaluronic acid, and therapeutic applications of same
    EP2254584A1|2010-12-01|Biocompatible injectable products with zinc and/or zinc-form saccharide-salt release, and uses thereof
    Gbassi et al.2013|Macrobeads based-polysaccharides: development and morphological analysis
    Łabowska et al.2020|Applications of alginates in the biomedical field
    WO2017098091A1|2017-06-15|Novel injectable composition; method for preparing said composition; use of said composition
    Ravi et al.2019|Alginates: current uses and future perspective
    EP3510050B1|2021-04-07|Anionically charged chitosan
    FR3088550A1|2020-05-22|IMPLANT HAVING CONTROLLED POROSITY IN HYBRID MATERIAL DOPED IN NUTRIENT OSTEOINDUCTOR
    Morris et al.2017|An investigation into the effects of pH and material concentrations on the morphology of Chitosan-Alginate microspheres prepared using an Ionic Gelation technique.
    Vecchies2019|DEVELOPMENT AND CHARACTERIZATION OF A POLYSACCHARIDES-BASE BIOMATERIAL FOR BIOMEDICAL APPLICATIONS
    CA3119242A1|2020-06-04|Biocompatible hydrogel, process for producing same, and use thereof in a mechanical viscosupplementation system
    同族专利:
    公开号 | 公开日
    US20170326275A1|2017-11-16|
    WO2016091778A1|2016-06-16|
    FR3029790B1|2017-01-13|
    EP3229777A1|2017-10-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE4122591C1|1991-07-08|1993-02-18|Roland 8012 Ottobrunn De Bodmeier|Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants|
    EP2361640A1|2010-02-25|2011-08-31|Université de Liège|Cell cultivation in chitosan alginate hydrogel beads|
    CN102920652A|2012-11-26|2013-02-13|昆明医科大学|Propolis and chitosan periodontal slow-release thermo-sensitive in-situ gel and preparation method thereof|
    CN103071156A|2012-12-12|2013-05-01|中国人民解放军第四军医大学|Chitosan wrapped negatively-charged gold nanoparticle, and preparation method and application thereof|
    WO2014094085A1|2012-12-21|2014-06-26|Universidade Estadual De Campinas - Unicamp|Method for obtaining chitosan-based products enriched with arrabidaea chica|
    BR112013012697A2|2010-11-23|2016-09-06|Georgia Tech Res Inst|"method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. "|
    EP2890399B1|2012-08-28|2019-11-06|University of Geneva|Hybrid hydrogels|KR101916193B1|2016-08-25|2018-11-07|주식회사 파마리서치프로덕트|Injectable composition comprising nucleic acid and chitosan for articular cavity|
    ES2671184B2|2016-11-16|2019-02-04|Univ Miguel Hernandez De Elche|FORMULATION FOR MODIFIED RELEASE OF ACTIVE SUBSTANCES OR DRUGS, USE AND PROCEDURE OF OBTAINING|
    CN109482110A|2017-09-12|2019-03-19|中国科学院兰州化学物理研究所苏州研究院|A kind of preparation method and application of aquagel|
    CN108125920A|2018-03-05|2018-06-08|清华大学|A kind of pill matrix microspheres material based on chitosan and preparation method thereof|
    CN108904467A|2018-08-01|2018-11-30|青岛农业大学|Chitosan-sodium phytate hollow Nano capsule preparation process and its application|
    KR102209051B1|2019-04-03|2021-01-28|국민대학교산학협력단|Chemical sensor including a hydrogel bead, container and electronic article including the chemical sensor|
    WO2021091040A1|2019-11-04|2021-05-14|주식회사 엔도비전|Hydrogel using mushroom- or fungus-derived chitosan, or derivatives thereof, and method for producing same|
    法律状态:
    2015-12-08| PLFP| Fee payment|Year of fee payment: 2 |
    2016-06-17| PLSC| Publication of the preliminary search report|Effective date: 20160617 |
    2016-10-07| CD| Change of name or company name|Owner name: SYNOLYNE PHARMA, BE Effective date: 20160905 |
    2016-12-06| PLFP| Fee payment|Year of fee payment: 3 |
    2018-03-29| PLFP| Fee payment|Year of fee payment: 4 |
    2019-12-19| PLFP| Fee payment|Year of fee payment: 6 |
    2020-12-23| PLFP| Fee payment|Year of fee payment: 7 |
    2021-12-24| PLFP| Fee payment|Year of fee payment: 8 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1462367A|FR3029790B1|2014-12-12|2014-12-12|CHITOSAN HYDROGEL MICROBELL|FR1462367A| FR3029790B1|2014-12-12|2014-12-12|CHITOSAN HYDROGEL MICROBELL|
    EP15807844.4A| EP3229777A1|2014-12-12|2015-12-07|Chitosan hydrogel microbead|
    US15/535,313| US20170326275A1|2014-12-12|2015-12-07|Chitosan Hydrogel Microbead|
    PCT/EP2015/078770| WO2016091778A1|2014-12-12|2015-12-07|Chitosan hydrogel microbead|
    [返回顶部]